Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Mathew S Maurer,Parag Kale,Marianna Fontana,John L Berk,Martha Grogan,Finn Gustafsson,Rebecca R Hung,Robert L Gottlieb,Thibaud Damy,Alejandra González-Duarte,Nitasha Sarswat,Yoshiki Sekijima,Nobuhiro Tahara,Mark S Taylor,Milos Kubanek,Erwan Donal,Tomas Palecek,Kenichi Tsujita,W H Wilson Tang,Wen-Chung Yu,Laura Obici,Marcus Simões,Fábio Fernandes,Steen Hvitfeldt Poulsen,Igor Diemberger,Federico Perfetto,Scott D Solomon,Marcelo Di Carli,Prajakta Badri,Matthew T White,Jihong Chen,Elena Yureneva,Marianne T Sweetser,Patrick Y Jay,Pushkal P Garg,John Vest,Julian D Gillmore,APOLLO-B Trial Investigators
DOI: https://doi.org/10.1056/NEJMoa2300757
2023-10-26
Abstract:Background: Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA interference therapeutic agent, inhibits the production of hepatic transthyretin. Methods: In this phase 3, double-blind, randomized trial, we assigned patients with hereditary, also known as variant, or wild-type ATTR cardiac amyloidosis, in a 1:1 ratio, to receive patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks for 12 months. A hierarchical procedure was used to test the primary and three secondary end points. The primary end point was the change from baseline in the distance covered on the 6-minute walk test at 12 months. The first secondary end point was the change from baseline to month 12 in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score (with higher scores indicating better health status). The second secondary end point was a composite of death from any cause, cardiovascular events, and change from baseline in the 6-minute walk test distance over 12 months. The third secondary end point was a composite of death from any cause, hospitalizations for any cause, and urgent heart failure visits over 12 months. Results: A total of 360 patients were randomly assigned to receive patisiran (181 patients) or placebo (179 patients). At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate of median difference, 14.69 m; 95% confidence interval [CI], 0.69 to 28.69; P = 0.02); the KCCQ-OS score increased in the patisiran group and declined in the placebo group (least-squares mean difference, 3.7 points; 95% CI, 0.2 to 7.2; P = 0.04). Significant benefits were not observed for the second secondary end point. Infusion-related reactions, arthralgia, and muscle spasms occurred more often among patients in the patisiran group than among those in the placebo group. Conclusions: In this trial, administration of patisiran over a period of 12 months resulted in preserved functional capacity in patients with ATTR cardiac amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO-B ClinicalTrials.gov number, NCT03997383.).